Eryilmaz Melek Karakurt, Mutlu Hasan, Salim Derya Kivrak, Musri Fatma Yalcin, Tural Deniz, Coskun Hasan Senol
Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, TurkeyE-mail :
Asian Pac J Cancer Prev. 2014;15(18):7737-40. doi: 10.7314/apjcp.2014.15.18.7737.
The neutrophil-to-lymphocyte ratio (NLR) is a strong predictor of mortality in patients with pancreatic, colorectal, lung, gastric cancer and renal cell carcinoma. The aim of this study was to determine the relationship between pathological complete response (pCR) and pretreatment NLR values in locally advanced breast cancer (BC) patients receiving neoadjuvant chemotherapy (NACT).
Datawere collected retrospectively from the Akdeniz University School of Medicine Database for locally advanced BC patients treated with NACT between January 2000- December 2013.
A total of 78 patients were analyzed. Sixteen (20%) patients achieved pCR. Estrogen receptor (ER) positivity was lower in pCR+ than pCR- cases (p=0.011). The median NLR values were similar in both arms. The optimum NLR cut-off point for BC patients with PCR+ was 2.33 (AUC:0.544, 95%CI [0.401- 0.688], p=0.586) with sensitivity, specificity, positive predictive value and negative predictive value (NPV) of 50%, 51,6%, 21,1%, and 80%, respectively.
This study showed no relationship between the pCR and pretreatment NLR values. Because of a considerable high NPV, in the patients with higher NLR who had luminal type BC in which pCR is lower after NACT, such treatment may not be recommended.
中性粒细胞与淋巴细胞比值(NLR)是胰腺癌、结直肠癌、肺癌、胃癌和肾细胞癌患者死亡率的有力预测指标。本研究旨在确定接受新辅助化疗(NACT)的局部晚期乳腺癌(BC)患者的病理完全缓解(pCR)与治疗前NLR值之间的关系。
回顾性收集2000年1月至2013年12月在阿克德尼兹大学医学院数据库中接受NACT治疗的局部晚期BC患者的数据。
共分析了78例患者。16例(20%)患者达到pCR。pCR+组的雌激素受体(ER)阳性率低于pCR-组(p=0.011)。两组的NLR中位数相似。PCR+的BC患者的最佳NLR切点为2.33(AUC:0.544,95%CI[0.401-0.688],p=0.586),敏感性、特异性、阳性预测值和阴性预测值(NPV)分别为50%、51.6%、21.1%和80%。
本研究表明pCR与治疗前NLR值之间无相关性。由于NPV相当高,对于NLR较高且为腔面型BC的患者,NACT后pCR较低,可能不建议进行此类治疗。